Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy

(E-pub Abstract Ahead of Print)

Author(s): Qin zhang, Ming Yang, Ying Xiao, Yachun Han, Shikun Yang, Lin Sun*.

Journal Name: Current Medicinal Chemistry


Diabetic nephropathy (DN) is one of the most common and important microvascular complications of diabetes mellitus (DM). The main clinical features of DN are proteinuria and a progressive decline in renal function , which are associated with structural and functional changes in the kidney. The pathogenesis of DN is multifactorial, including genetic, metabolic and haemodynamic factors, which can trigger a sequence of events. Controlling metabolic risks such as hyperglycaemia, hypertension and dyslipidaemia is not enough to slow the progression of DN. Recent studies have emphasized immunoinflammation as a critical pathogenic factor in the progression of DN. Therefore, targeting inflammation is considered a potential and novel treatment strategy for DN. In this review, we will briefly introduce the inflammatory process of DN and discuss the anti-inflammatory effects of antidiabetic drugs when treating DN.

Keywords: Diabetic nephropathy, immunoinflammatory, metformin, stains, glucagon-like peptide-1 analogue, spironolactone, phosphodiesterase inhibitors, vitamin D

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Abstract Ahead of Print)
DOI: 10.2174/0929867326666191108160643
Price: $95